Внесок користувача
- 16:01, 21 квітня 2017 (різн. • історія) . . (+3116) . . Н In addition, the clinical version of RGDfV, Cilengitide, is in clinical trials, underscoring the ought to fully have an understanding of the molecular mechanism that are affected by RGDfV (Створена сторінка: m ChinaPeptides Co.. The Ni-NTA Resin was from Bio Simple Inc. The monoclonal anti-His, anti-Myc and anti-actin antibodies had been from Santa Cruz Biotech. Ant...) (поточна)